CD44 splice isoform switching determines breast cancer stem cell state

Honghong Zhang, Rhonda L. Brown, Yong Wei, Pu Zhao, Sali Liu, Xuan Liu, Yu Deng, Xiaohui Hu, Jing Zhang, Xin D. Gao, Yibin Kang, Arthur M. Mercurio, Hira Lal Goel, Chonghui Cheng

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Although changes in alternative splicing have been observed in cancer, their functional contributions still remain largely unclear. Here we report that splice isoforms of the cancer stem cell (CSC) marker CD44 exhibit strikingly opposite functions in breast cancer. Bioinformatic annotation in patient breast cancer in The Cancer Genome Atlas (TCGA) database reveals that the CD44 standard splice isoform (CD44s) positively associates with the CSC gene signatures, whereas the CD44 variant splice isoforms (CD44v) exhibit an inverse association. We show that CD44s is the predominant isoform expressed in breast CSCs. Elimination of the CD44s isoform impairs CSC traits. Conversely, manipulating the splicing regulator ESRP1 to shift alternative splicing from CD44v to CD44s leads to an induction of CSC properties. We further demonstrate that CD44s activates the PDGFRβ/Stat3 cascade to promote CSC traits. These results reveal CD44 isoform specificity in CSC and non-CSC states and suggest that alternative splicing provides functional gene versatility that is essential for distinct cancer cell states and thus cancer phenotypes.

Original languageEnglish (US)
Pages (from-to)166-179
Number of pages14
JournalGenes and Development
Volume33
Issue number3-4
DOIs
StatePublished - Feb 2019

All Science Journal Classification (ASJC) codes

  • Genetics
  • Developmental Biology

Keywords

  • Alternative splicing
  • Breast cancer
  • CD44s
  • CSC
  • PDGFRβ/Stat3

Fingerprint Dive into the research topics of 'CD44 splice isoform switching determines breast cancer stem cell state'. Together they form a unique fingerprint.

Cite this